Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
Du musst dich anmelden oder registrieren, bevor du fortfahren kannst.
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

How Biogen Inc. Makes Most of Its Money

TheMotleyFool 
0 0 13.07.17
How Biogen Inc. Makes Most of Its MoneyPhoto, wide shot, wide-angle lens, soft focus, Clinical research organization, Blue hour, twilight, cool, ISO1200, slow shutter speed, photo by Hiroshi Sugimoto: https://oaidalleapiprodscus.blob.core.windows.net/private/org-IbuNdCATsFaPOITjFOv2kJh3/user-AXaxqjBUW45D8BadJEo9mUpW/img-d5U47McddROtnUwv1JIaZvc2.png?st=2023-05-04T16%3A11%3A57Z&se=2023-05-04T18%3A11%3A57Z&sp=r&sv=2021-08-06&sr=b&rscd=inline&rsct=image/png&skoid=6aaadede-4fb3-4698-a8f6-684d7786b067&sktid=a48cca56-e6da-484e-a814-9c849652bcb3&skt=2023-05-04T16%3A04%3A37Z&ske=2023-05-05T16%3A04%3A37Z&sks=b&skv=2021-08-06&sig=KvGLXJQj4L2uYw31IYBsPpHX4telRq/7natMW2uEF58%3D
 

Biogen (NASDAQ: BIIB) recorded $2.38 billion in product revenue in the first quarter -- a nice haul for a large biotech -- but 40% of its sales came from its top-selling multiple-sclerosis drug Tecfidera.

Drug

First-Quarter 2017 Sales

Continue reading


Source: Fool.com

Gilead Sciences Inc Stock

€117.26
2.670%
Gilead Sciences Inc gained 2.670% today.
The stock is an absolute favorite of our community with 65 Buy predictions and no Sell predictions.
With a target price of 128 € there is a slightly positive potential of 9.16% for Gilead Sciences Inc compared to the current price of 117.26 €.
Show more
Like: 0
GILD
Share

Comments

Not a member yet? Sign up for free!